ArticleNeurochemical research2026
Downregulation of lncRNA SNHG14 Alleviates Neuropathic Pain and Inflammation in CCI Rats by Targeting miR-182-5p/BDNF.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory processes hold significant importance for the initiation and long-term maintenance of neuropathic pain (NP). This study aimed to investigate the function of long non-coding RNA SNHG14 in NP and the regulatory mechanism underlying its action via the miR-182-5p/ brain-derived neurotrophic factor (BDNF) axis. 80 serum samples were collected from NP patients and 80 from healthy controls, followed by the detection of SNHG14 expression. A chronic constriction injury (CCI) rat model of the sciatic nerve was established, and animals were assigned to experimental groups for behavioral, molecular, and biochemical analyses, including assessment of mechanical and thermal pain thresholds, quantitative reverse transcription polymerase chain reaction (RT-qPCR), and enzyme-linked immunosorbent assay (ELISA). RNA immunoprecipitation (RIP), and dual-luciferase assays were used to verify the targeted relationship. In both NP patients and CCI rats, SNHG14 expression was significantly upregulated and showed preliminary diagnostic potential, warranting further validation in larger cohorts. Silencing SNHG14 effectively alleviated pain-related behaviors and concurrently reduced the levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Mechanistic investigations revealed that SNHG14 exerted its regulatory effects by directly binding to and negatively modulating miR-182-5p, which in turn targeted and suppressed BDNF expression. Functional rescue experiments indicated that antagomir-miR-182-5p partially reversed the analgesic and anti-inflammatory effects achieved through SNHG14 knockdown. Conversely, BDNF silencing partially counteracted the hyperalgesia and enhanced inflammatory responses induced by antagomir-miR-182-5p. SNHG14 upregulated BDNF expression by sequestering miR-182-5p, thereby enhancing the hyperalgesic response and neuroinflammatory processes in NP and CCI rats.
Indexed as
Identifiers
42228285What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.